Prescription of alfa-lipoic acid to the patients with diabetic neuropathy in accordance with evidence-based medicine

Authors: Daniela Adamkovičová 1;  Martin Selvek 1;  Roman Mužik 1;  Ivan Tkáč 2
Authors‘ workplace: DÔVERA zdravotná poisťovňa, a. s., Bratislava 1;  Excelentný tím pre výskum aterosklerózy (EXTASY), IV. interná klinika UPJŠ LF a UN LP, Košice 2
Published in: Forum Diab 2023; 12(1): 55-58


Diabetic neuropathy is one of the most common comorbidities of diabetes. One of the agents used in its treatment is alpha-lipoic acid (ALA). From several studies investigating the dose-dependence of its effect, a dose of 600 mg daily has been shown to be optimal. The prescriptions of ALA in the years 2017–2022 were analyzed based on the data of the health insurance company Dôvera. In patients on regular ALA treatment, the daily dose of ALA used was determined based on the prescription. In 2022, of the 8,281 patients on regular ALA, 43.8 % were on a dose greater than 600 mg per day and 6.1 % were on a dose greater than 900 mg per day. Patients who had ALA prescriptions from multiple physicians were statistically significantly more likely to be taking a higher than recommended dose. It can be observed of the health insurance data that a significant proportion of patients are taking higher than recommended doses of ALA. Although the proportion of patients on a dose of ALA greater than 600 mg is decreasing, physicians need to be proactive in preventing accumulation of prescriptions in patients.


diabetic neuropathy – alpha-lipoic acid – optimal dose


1. Tkáč I, Bril V. Glycemic control is related to the electrophysiologic severity of diabetic peripheral sensorimotor polyneuropathy. Diabetes Care 1998; 21(10): 1749–1752. Dostupné z DOI: <>.

2. Mizukami H, Osonoi S. Pathogenesis and Molecular Treatment Strategies of Diabetic Neuropathy Collateral Glucose-Utilizing Pathways in Diabetic Polyneuropathy. Int J Mol Sci 2021; 22(1): 94. Dostupné z DOI: <>.

3. Vinik A, Nevoret M-L, Casellini C et al. Diabetic neuropathy. Endocr Metab Clin North Am 2013; 42(4): 747–787. Dostupné z DOI: <>.

4. Papanas N, Ziegler D. Efficacy of a-lipoic acid in diabetic neuropathy. Expert Opin Pharmacother 2014; 15(18): 2721–2731. Dostupné z DOI: <>.

5. Ziegler D, Hanefeld M, Ruhnau KJ et al. Treatment of the symptomatic diabetic neuropathy with anti-oxidant alpha-lipoic acid. 3-week multicentre randomised controlled trial (ALDIN Study). Diabetologia 1995; 38(12): 1425–1433. Dostupné z DOI: <>.

6. Reljanovc M, Reichel G, Rett K et al. Treatment of diabetic polyneuropathy with the anti-oxidant thioctic acid (alpha-lipoic acid): a two-year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha-Lipoic Acid in Diabetic Neuropathy. Free Rad Res 1999; 31(3): 171–179. Dostupné z DOI: <>.

7. Ziegler D, Ametov A, Barinov A et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 2006; 29(11): 2365–2370. Dostupné z DOI: <–1216>.

8. Thioctacid 600 HR. Súhrn charakteristických vlastností lieku. Dostupné z WWW: <>.

9. Halpern MT, Khan ZM, Schmier JK et al. Recommendations for Evaluating Compliance and Persistence With Hypertension Therapy Using Retrospective Data. Hypertension 2006; 47(6): 1039–1048. Dostupné z DOI: <>.

10. SSVPL. Odporúčania členom SSVPL týkajúce sa delegovaného predpisovania od 1.1.2022. Dostupné z WWW: <–1-2022>.

11. Ziegler D, Low PA, Litchy VJ et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care 2011; 34(9): 2054–2060. Dostupné z DOI: <–0503>.

12. Chua KP, Brummet CM, Ng S et al. Association Between Receipt of Overlapping Opioid and Benzodiazepine Prescriptions From Multiple Prescribers and Overdose Risk. JAMA Netw Open 2021; 4(8): e2120353. Dostupné z DOI: <>.

Diabetology Endocrinology Internal medicine
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account